BIXT
Bioxytran, Inc.
Price Chart
Latest Quote
$0.03
+0.00 (+0.00%)
Current Price
| Previous Close | $0.03 |
| Open | $0.03 |
| Day High | $0.03 |
| Day Low | $0.03 |
| Volume | 60,000 |
Stock Information
| Shares Outstanding | 114.20M |
| Total Debt | $1.21M |
| Cash Equivalents | $463K |
| Net Income | $-2.84M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.43M |
| EPS (TTM) | $-0.02 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $4.22M |
| Income | $-2.84M |
| Book/sh | $-0.04 |
| Cash/sh | $0.00 |
| Employees | 2 |
Financial Ratios
| Quick Ratio | 0.09 |
| Current Ratio | 0.09 |
Returns & Margins
| ROA | -544.42% |
Ownership
| Insider Ownership | 0.62% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -0.77 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.03 |
| SMA50 | $0.04 |
| SMA200 | $0.06 |
| RSI | 33.85 |
| ATR | 0.0019 |
| Shares Float | 113.48M |
| Volatility | 1.82 |
Performance History
| Week | -5.66% |
| Month | +3.45% |
| Quarter | -31.82% |
| 6 Months | -59.02% |
| YTD | -58.30% |
| Year | -78.56% |
| 3 Years | -90.54% |
| 5 Years | +2900.00% |
| 10 Years | -98.67% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-04 | $0.03 | 0 |
| 2026-06-03 | $0.03 | 107,251 |
| 2026-06-02 | $0.03 | 51,500 |
| 2026-06-01 | $0.03 | 13,649 |
| 2026-05-29 | $0.03 | 0 |
| 2026-05-28 | $0.03 | 402 |
| 2026-05-27 | $0.03 | 35,617 |
| 2026-05-26 | $0.03 | 107,050 |
| 2026-05-22 | $0.03 | 16,780 |
| 2026-05-21 | $0.03 | 1,685 |
| 2026-05-20 | $0.03 | 5,524 |
| 2026-05-19 | $0.03 | 89,251 |
| 2026-05-18 | $0.03 | 4,660 |
| 2026-05-15 | $0.03 | 4,000 |
| 2026-05-14 | $0.03 | 2,500 |
| 2026-05-13 | $0.03 | 1,805 |
| 2026-05-12 | $0.04 | 30,627 |
| 2026-05-11 | $0.04 | 27,400 |
| 2026-05-08 | $0.03 | 14,602 |
| 2026-05-07 | $0.04 | 3,423 |
| 2026-05-06 | $0.03 | 38,755 |
| 2026-05-05 | $0.03 | 164,265 |
About Bioxytran, Inc.
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address viral infections, glycovirology, and oxygen delivery, hypoxia and degenerative diseases in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-3, a type of galectin for treatment of mild to moderate cases of Covid-19. Bioxytran, Inc. has collaboration with University of Minnesota for advance novel carbohydrate-based therapeutics. The company was founded in 2008 and is headquartered in Needham, Massachusetts.
đ° Latest News
No news articles available at the moment. Check back later for updates on BIXT.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $770,361 | $541,828 | $526,321 | $313,608 |
| Total Expenses | $2,231,018 | $3,808,497 | $2,440,185 | $4,214,434 |
| Other Income Expense | $621,374 | $-212,458 | $300,000 | - |
| Net Non Operating Interest Income Expense | $-770,361 | $-541,828 | $-526,321 | $-313,608 |
| Interest Expense Non Operating | $770,361 | $541,828 | $526,321 | $313,608 |
| Operating Expense | $2,231,018 | $3,808,497 | $2,440,185 | $4,214,434 |
| Selling And Marketing Expense | $336,125 | $595,448 | $339,251 | - |
| General And Administrative Expense | $1,774,606 | $2,055,555 | $819,522 | $2,200,672 |
| Other Non Operating Income Expenses | - | - | $300,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-2,366,681 | $-4,472,525 | $-2,473,134 | $-4,031,745 |
| Net Interest Income | $-770,361 | $-541,828 | $-526,321 | $-313,608 |
| Normalized Income | $-2,988,055 | $-4,260,067 | $-2,473,134 | $-4,031,745 |
| Net Income From Continuing And Discontinued Operation | $-2,366,681 | $-4,472,525 | $-2,473,134 | $-4,031,745 |
| Total Operating Income As Reported | $-2,223,068 | $-3,800,212 | $-2,436,541 | $-4,214,434 |
| Net Income Common Stockholders | $-2,366,681 | $-4,472,525 | $-2,473,134 | $-4,031,745 |
| Net Income | $-2,366,681 | $-4,472,525 | $-2,473,134 | $-4,031,745 |
| Net Income Including Noncontrolling Interests | $-2,380,005 | $-4,562,783 | $-2,666,506 | $-4,528,042 |
| Net Income Continuous Operations | $-2,380,005 | $-4,562,783 | $-2,666,506 | $-4,528,042 |
| Pretax Income | $-2,380,005 | $-4,562,783 | $-2,666,506 | $-4,528,042 |
| Special Income Charges | $488,253 | $-212,458 | $0 | - |
| Operating Income | $-2,231,018 | $-3,808,497 | $-2,440,185 | $-4,214,434 |
| Depreciation Amortization Depletion Income Statement | $7,950 | $8,285 | $3,644 | $0 |
| Depreciation And Amortization In Income Statement | $7,950 | $8,285 | $3,644 | $0 |
| Amortization Of Intangibles Income Statement | $7,950 | $8,285 | $3,644 | $0 |
| Per Share | ||||
| Diluted EPS | $-0.02 | $-0.03 | $-0.02 | $-0.04 |
| Basic EPS | $-0.02 | $-0.03 | $-0.02 | $-0.04 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,223,068 | $-3,800,212 | $-2,136,541 | $-4,214,434 |
| Total Unusual Items | $621,374 | $-212,458 | $0 | - |
| Total Unusual Items Excluding Goodwill | $621,374 | $-212,458 | $0 | - |
| Reconciled Depreciation | $7,950 | $8,285 | $3,644 | $0 |
| EBITDA (Bullshit earnings) | $-1,601,694 | $-4,012,670 | $-2,136,541 | $-4,214,434 |
| EBIT | $-1,609,644 | $-4,020,955 | $-2,140,185 | $-4,214,434 |
| Diluted Average Shares | $138,598,691 | $133,973,352 | $112,712,305 | $106,252,116 |
| Basic Average Shares | $138,598,691 | $133,973,352 | $112,712,305 | $106,252,116 |
| Diluted NI Availto Com Stockholders | $-2,366,681 | $-4,472,525 | $-2,473,134 | $-4,031,745 |
| Minority Interests | $13,324 | $90,258 | $193,372 | $496,297 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Other Special Charges | $-488,253 | $212,458 | - | - |
| Gain On Sale Of Security | $133,121 | - | - | - |
| Amortization | $7,950 | $8,285 | $3,644 | $0 |
| Research And Development | $112,337 | $1,149,209 | $1,277,768 | $2,013,762 |
| Selling General And Administration | $2,110,731 | $2,651,003 | $1,158,773 | $2,200,672 |
| Other Gand A | $557,579 | $451,551 | $433,506 | $1,617,810 |
| Salaries And Wages | $1,217,027 | $1,604,004 | $386,016 | $582,862 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,925,488 | $-2,537,266 | $-2,781,882 | $-2,807,883 |
| Total Assets | $138,694 | $139,382 | $370,936 | $119,290 |
| Total Non Current Assets | $133,540 | $113,296 | $75,535 | $46,932 |
| Goodwill And Other Intangible Assets | $133,540 | $113,296 | $75,535 | $46,932 |
| Other Intangible Assets | $133,540 | $113,296 | $75,535 | $46,932 |
| Current Assets | $5,154 | $26,086 | $295,401 | $72,358 |
| Cash Cash Equivalents And Short Term Investments | $5,154 | $26,086 | $295,401 | $72,358 |
| Cash And Cash Equivalents | $5,154 | $26,086 | $295,401 | $72,358 |
| Cash Financial | $5,154 | $26,086 | $295,401 | $72,358 |
| Prepaid Assets | - | - | - | $0 |
| Debt | ||||
| Net Debt | $1,088,924 | $1,898,914 | $1,869,599 | $2,049,823 |
| Total Debt | $1,094,078 | $1,925,000 | $2,165,000 | $2,122,181 |
| Current Debt And Capital Lease Obligation | $1,094,078 | $1,925,000 | $2,165,000 | $2,122,181 |
| Current Debt | $1,094,078 | $1,925,000 | $2,165,000 | $2,122,181 |
| Other Current Borrowings | $1,094,078 | $1,925,000 | $2,165,000 | $2,122,181 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,930,642 | $3,244,238 | $3,667,911 | $3,277,497 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $1,930,642 | $3,244,238 | $3,667,911 | $3,277,497 |
| Other Current Liabilities | $411,020 | $1,014,557 | $39,360 | $375,371 |
| Payables And Accrued Expenses | $351,044 | $304,681 | $1,282,994 | $1,024,066 |
| Interest Payable | $150,592 | $223,759 | $134,581 | $85,685 |
| Payables | $159,592 | $3,658 | $750,899 | $563,010 |
| Total Tax Payable | $11,945 | $0 | $40,182 | $32,010 |
| Accounts Payable | $361 | $1,658 | $990 | $0 |
| Equity | ||||
| Common Stock Equity | $-1,835,106 | $-2,423,970 | $-2,706,347 | $-2,760,951 |
| Preferred Stock Equity | $43,158 | - | - | - |
| Total Equity Gross Minority Interest | $-1,791,948 | $-3,104,856 | $-3,296,975 | $-3,158,207 |
| Stockholders Equity | $-1,791,948 | $-2,423,970 | $-2,706,347 | $-2,760,951 |
| Retained Earnings | $-18,921,168 | $-15,699,327 | $-11,226,802 | $-8,753,668 |
| Other Equity Interest | - | $45,000 | - | - |
| Other | ||||
| Ordinary Shares Number | $86,782,908 | $145,642,333 | $123,252,235 | $110,840,998 |
| Share Issued | $86,782,908 | $145,642,333 | $123,252,235 | $110,840,998 |
| Tangible Book Value | $-1,968,646 | $-2,537,266 | $-2,781,882 | $-2,807,883 |
| Invested Capital | $-741,028 | $-498,970 | $-541,347 | $-638,770 |
| Working Capital | $-1,925,488 | $-3,218,152 | $-3,372,510 | $-3,205,139 |
| Total Capitalization | $-1,791,948 | $-2,423,970 | $-2,706,347 | $-2,760,951 |
| Minority Interest | $0 | $-680,886 | $-590,628 | $-397,256 |
| Additional Paid In Capital | $16,999,279 | $13,085,715 | $8,397,109 | $5,881,876 |
| Capital Stock | $129,941 | $144,642 | $123,346 | $110,841 |
| Common Stock | $86,783 | $144,642 | $123,346 | $110,841 |
| Preferred Stock | $43,158 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $74,500 | $0 | $180,557 | $131,250 |
| Current Accrued Expenses | $191,452 | $301,023 | $532,095 | $461,056 |
| Dueto Related Parties Current | $147,286 | $2,000 | $709,727 | $531,000 |
| Treasury Shares Number | - | $0 | - | - |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-83,932 | $-819,676 | $-1,835,917 | $-1,734,330 |
| Operating Activities | ||||
| Operating Cash Flow | $-55,737 | $-775,375 | $-1,803,670 | $-1,697,399 |
| Cash Flow From Continuing Operating Activities | $-55,737 | $-775,375 | $-1,803,670 | $-1,697,399 |
| Operating Gains Losses | $-386,129 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-28,195 | $-44,301 | $-32,247 | $-36,931 |
| Investing Cash Flow | $-28,195 | $-44,301 | $-32,247 | $-36,931 |
| Cash Flow From Continuing Investing Activities | $-28,195 | $-44,301 | $-32,247 | $-36,931 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $63,000 | $550,361 | $678,000 | $600,000 |
| Financing Cash Flow | $63,000 | $550,361 | $2,058,960 | $1,765,000 |
| Cash Flow From Continuing Financing Activities | $63,000 | $550,361 | $2,058,960 | $1,765,000 |
| Net Common Stock Issuance | $63,000 | $550,361 | $678,000 | $600,000 |
| Common Stock Issuance | $63,000 | $550,361 | $678,000 | $600,000 |
| Other | ||||
| Interest Paid Supplemental Data | $164,447 | $52,425 | $104,850 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $5,154 | $26,086 | $295,401 | $72,358 |
| Beginning Cash Position | $26,086 | $295,401 | $72,358 | $41,688 |
| Changes In Cash | $-20,932 | $-269,315 | $223,043 | $30,670 |
| Net Intangibles Purchase And Sale | $-28,195 | $-44,301 | $-32,247 | $-36,931 |
| Purchase Of Intangibles | $-28,195 | $-44,301 | $-32,247 | $-36,931 |
| Change In Working Capital | $1,226,195 | $3,201,477 | $308,235 | $2,170,750 |
| Change In Payables And Accrued Expense | $1,226,195 | $2,215,573 | $308,235 | $1,896,035 |
| Change In Payable | $1,226,195 | $2,215,573 | $308,235 | $1,896,035 |
| Change In Account Payable | $1,226,195 | $2,215,573 | $308,235 | $1,896,035 |
| Other Non Cash Items | $842,228 | $400,225 | $372,575 | $77,031 |
| Stock Based Compensation | $634,024 | $177,421 | $178,382 | $582,862 |
| Depreciation Amortization Depletion | $7,950 | $8,285 | $3,644 | $0 |
| Depreciation And Amortization | $7,950 | $8,285 | $3,644 | $0 |
| Amortization Cash Flow | $7,950 | $8,285 | $3,644 | $0 |
| Amortization Of Intangibles | $7,950 | $8,285 | $3,644 | $0 |
| Gain Loss On Investment Securities | $-386,129 | - | - | - |
| Net Income From Continuing Operations | $-2,380,005 | $-4,562,783 | $-2,666,506 | $-4,528,042 |
| Issuance Of Debt | - | $0 | $1,380,960 | $1,165,000 |
| Net Issuance Payments Of Debt | - | $0 | $1,380,960 | $1,165,000 |
| Net Long Term Debt Issuance | - | $0 | $1,380,960 | $1,165,000 |
| Long Term Debt Issuance | - | $0 | $1,380,960 | $1,165,000 |
| Change In Other Working Capital | - | $985,904 | - | - |
| Change In Other Current Liabilities | - | $485,904 | $0 | - |
| Change In Prepaid Assets | - | - | $0 | $274,715 |
| Repayment Of Debt | - | - | - | $0 |
| Net Short Term Debt Issuance | - | - | - | $1,165,000 |
| Short Term Debt Issuance | - | - | - | $1,165,000 |
| Long Term Debt Payments | - | - | - | $0 |
| Change In Receivables | - | - | - | $0 |
Fetched: 2026-02-02